Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.38 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10096670 | 0.87 | MAPK14 (0.41) | MAPK14KDM4EALDH1A1HPGDTHRB | |
| SCHEMBL13151803 | 0.84 | HPGD (0.43) | KDM4EALDH1A1HPGDSMN1; SMN2CYP2C9 | |
| SCHEMBL13052084 | 0.82 | HPGD (0.54) | KDM4EALDH1A1HPGDRORCACSS2 | |
| SCHEMBL10097730 | 0.81 | MEN1 (0.41) | ALDH1A1CYP2C9MEN1KMT2A | |
| SCHEMBL13151830 | 0.81 | HPGD (0.39) | ALDH1A1HPGD | |
| SCHEMBL13198721 | 0.80 | TSHR (0.43) | MAPK14KDM4EALDH1A1HPGDTHRB | |
| SCHEMBL13051526 | 0.79 | ALDH1A1 (0.43) | KDM4EALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL13152728 | 0.79 | JAK2 (0.41) | KDM4EALDH1A1HPGDTHRBSMN1; SMN2 | |
| SCHEMBL14376745 | 0.78 | PLK4 (0.42) | KDM4EALDH1A1HPGD | |
| SCHEMBL14468112 | 0.76 | HPGD (0.46) | KDM4EALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | MAPK14 4249/4885KDM4E 4020/4885ALDH1A1 1497/4885 |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | MAPK14 3075/4885KDM4E 4208/4885ALDH1A1 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.